GemPharmatech Co., Ltd. Class A 688046
SSE · China · Health Technology
CNY 37.94+2.96 (+8.46%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SEOUL, South Korea, July 22, 2026--GCCL, a South Korea-based leading provider of clinical trial sample analysis, and GemPharmatech, a global provider of in vivo efficacy testing and genetically engineered animal models, announced the signing of a Memorandum of Understanding (MOU) to promote mutual collaboration in delivering integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide.
SINGAPORE & SAN DIEGO, July 15, 2026--GemPharmatech, an international provider of in vivo efficacy testing and genetically engineered animal models, and Humlab Global, a Singapore-based developer of humanized mouse models and translational research solutions, today announced the signing of an agreement for the global distribution of existing and novel humanized strains.
Hangzhou, China, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today is pleased to announce that its subsidiary, Neologics Bioscience Inc. (“Neologics”), has entered into a key service agreement (the “Agreement”) with GemPharmatech Corporation (“GemPharmatech”), a Delaware-based
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.